Werbung
Werbung

CBIO

CBIO logo

Crescent Biopharma, Inc. Common Stock

10.81
USD
Gesponsert
-0.16
-1.41%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

10.80

-0.01
-0.09%

CBIO Ergebnisberichte

Positives Überraschungsverhältnis

CBIO übertreffen die 29 der letzten 38Schätzungen.

76%

Nächster Bericht

Datum des nächsten Berichts
09. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.10M
/
-$2.51
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
+97.64%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
--

Crescent Biopharma, Inc. Common Stock earnings per share and revenue

On 06. Nov. 2025, CBIO reported earnings of -1.27 USD per share (EPS) for Q3 25, beating the estimate of -2.02 USD, resulting in a 37.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.39% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -2.51 USD, with revenue projected to reach 5.10 million USD, implying an increase of 97.64% EPS, and -- of --% in Revenue from the last quarter.
FAQ
For Q3 2025, Crescent Biopharma, Inc. Common Stock reported EPS of -$1.27, beating estimates by 37.18%, and revenue of $0.00, 0% as expectations.
The stock price moved up 5.39%, changed from $12.43 before the earnings release to $13.10 the day after.
The next earning report is scheduled for 09. Feb. 2026.
Based on 8 analysts, Crescent Biopharma, Inc. Common Stock is expected to report EPS of -$2.51 and revenue of $5.10M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung